Asymmetrical myocardial expression of natriuretic peptides in pacing-induced heart failure

Silvia Del Ry1, Manuela Cabiati, Vincenzo Lionetti

  • 1CNR Institute of Clinical Physiology and G. Monasterio Foundation-CNR Regione Toscana, Via Giuseppe Moruzzi 1, Pisa, Italy. delry@ifc.cnr.it

Peptides
|June 23, 2009
PubMed

Insights

High-frequency pacing induces heart failure with regional contractility differences. Brain natriuretic peptide (BNP) mRNA increased at the pacing site, while C-type natriuretic peptide (CNP) expression rose in remote areas, suggesting regional dysfunction.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Biochemistry

Background:

  • Left ventricular (LV) free wall pacing induces dyssynchronous contraction, leading to heart failure (HF).
  • Regional differences in contractility are pronounced in pacing-induced HF.
  • Brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) are key biomarkers in cardiovascular disease.

Purpose of the Study:

  • To evaluate changes in BNP and CNP mRNA expression in pacing-induced HF minipigs.
  • To compare biomarker expression between the pacing site (PS) and the opposite site (OS).
  • To explore associations between regional contractility patterns and biomarker expression.

Main Methods:

  • Cardiac tissue samples were collected from minipigs with (n=8) and without (n=6) pacing-induced HF.
  • Tissue was harvested from the anterior LV wall (PS) and the infero-septal region (OS).
  • Semi-quantitative polymerase chain reaction (PCR) was used to assess BNP and CNP mRNA expression.

Main Results:

  • BNP mRNA expression was significantly higher at the PS in HF animals compared to controls (p=0.02).
  • No significant difference in BNP mRNA was observed at the OS.
  • CNP mRNA expression and tissue concentration were elevated at both PS and OS in HF animals, particularly at the OS (p=0.039).

Conclusions:

  • Increased BNP mRNA at the PS correlates with reduced contractile function in the paced region.
  • Elevated CNP mRNA and concentration at the OS suggest concomitant endothelial dysfunction in remote myocardial areas.
  • These findings highlight regional molecular adaptations in pacing-induced heart failure.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...